Search
Search Results
-
GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion
Aims/hypothesisDiabetes mellitus is associated with impaired insulin secretion, often aggravated by oversecretion of glucagon. Therapeutic...
-
Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels
Weight regain and insufficient weight loss are essential problems after metabolic bariatric surgery (MBS) in people living with obesity. Changes in...
-
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
Glucagon-like peptide-1 receptor analogs (GLP-1 RAs) have been an innovative and instrumental drug class in the management of both type 2 diabetes...
-
„Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?
Obesity is a chronic disease with a high and still increasing prevalence and many comorbidities, making it a growing global problem. Achieving...
-
Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study
ObjectiveLittle is known about the effect of a multi-drug weight loss strategy in obesity treatment, particularly combining bupropion/naltrexone and...
-
Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions
Scientists were chasing an incretin hormone, and when GLP-1 was finally discovered, we found that it had a pronounced satiety effect, slowed down...
-
Sindrome dell’ovaio policistico: ruolo del glucagon-like peptide 1 (GLP-1) nella regolazione dell’asse ipotalamo-ipofisi-ovaio
Obesity and insulin resistance associated to Polycystic Ovary Syndrome (PCOS) prompted the development of clinical studies evaluating the...
-
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Purpose of ReviewGlucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining importance due to their effects on cardiovascular parameters. This...
-
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Aims/hypothesisInsulin is the primary treatment for type 1 diabetes. However, alternative glucose-lowering therapies are used adjunctively, but...
-
Common food additive carrageenan inhibits proglucagon expression and GLP-1 secretion by human enteroendocrine L-cells
Proglucagon mRNA expression and GLP-1 secretion by cultured human L-cells (NCI-H716) were inhibited following exposure to λ-carrageenan, a commonly...
-
Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature
Glucagon-like-peptide-1 (GLP-1) agonists are an emerging class of medications used to manage type 2 diabetes mellitus (T2DM) and weight loss, with...
-
GLP-1 in patients with myocardial infarction complicated by cardiogenic shock—an IABP-SHOCK II-substudy
BackgroundGlucagon-like peptide-1 (GLP-1) is a gut-derived peptide secreted in response to nutritional and inflammatory stimuli. Elevated GLP-1...
-
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to...
-
The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight
BackgroundGLP-1 receptor agonists (GLP-1 RAs) have dramatically altered obesity treatment. Media reports suggest that GLP-1 RAs users often report...
-
Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
BackgroundGlucagon is secreted from pancreatic alpha cells in response to low blood glucose and increases hepatic glucose production. Furthermore,...
-
The role of the HERG channel in the secretion of glucagon-like peptide-1 (GLP-1) from murine intestinal L-cells
The HERG ion channel belongs to the voltage-gated potassium (Kv) channel family and is involved in potassium efflux during cellular repolarization....
-
Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study
IntroductionBody mass index (BMI) > 50 kg/m 2 is associated with relatively increased morbidity and mortality with bariatric surgery (BS). There is...
-
Idiopathic Intracranial Hypertension After Abrupt Cessation of Medication: A Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Cessation and Review of the Literature
Purpose of ReviewThe purpose of this review is two-fold: (1) to discuss a case report of idiopathic intracranial hypertension (IIH) after abrupt...
-
One anastomosis gastric bypass ameliorates diabetic nephropathy via regulating the GLP-1-mediated Sirt1/AMPK/PGC1α pathway
BackgroundDiabetic nephropathy (DN), a complication of diabetes, is the most leading cause of end-stage renal disease. Bariatric surgery functions on...
